Join our Free Newsletter and unlock 50% off AltIndexFree newsletter + 50% offJoin free
$109M 2516%Beat EPS +387.1%
Total revenue, Q1 '25 ().

Did Century Therapeutics Beat Earnings?

Century Therapeutics (IPSC) reported Q1 '25 revenue of $109M, up 12,667.7% year-over-year, with reported EPS of $0.89. That topped the $-0.31 analyst estimate by 387.1% — an earnings beat.

AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Century Therapeutics’s job postings, web traffic, and employee business outlook. See the full IPSC stock analysis or the earnings calendar for upcoming reports.

Century Therapeutics Quarterly Financial Trends ()

MetricQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Revenue790,0004.2M109M—————
Gross margin100.0%100.0%100.0%—————
Operating margin-4,398.1%-893.5%67.9%—————
Net income-31M-36M77M-33M-34M-19M-22M-35M
Net margin-3,947.7%-864.4%70.1%—————
EPS——$0.89—————

Century Therapeutics Earnings Trend Analysis

Over the eight quarters from Q3 '24 to Q2 '26, Century Therapeutics’s quarterly revenue moved from $790,000 to $0. Century Therapeutics has beaten Wall Street EPS estimates in 1 of its last 1 reported quarters.

When Is Century Therapeutics’s Next Earnings Date?

Century Therapeutics reports earnings on a quarterly schedule. Its most recent report covered Q1 '25. For the confirmed upcoming date — and every other company reporting soon — see the IPSC earnings calendar.

Frequently Asked Questions: Century Therapeutics Earnings

Century Therapeutics's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.

Century Therapeutics reported Q1 '25 EPS of $0.89 on revenue of $109M (+12,667.7% YoY). Century Therapeutics beat estimates, reporting $0.89 vs. the $-0.31 estimate.

Century Therapeutics reported Q1 '25 revenue of $109M, up 12,667.7% from the same quarter a year earlier.

Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the IPSC AI Score.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.